Abstract: Provided is an antibody or an antigen-binding fragment thereof that binds to human TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains). Also provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and host cell containing the nucleic acid molecule, an immunoconjugate and composition comprising the antibody or the antigen-binding fragment thereof, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a product for positively adjusting the activity of immune cells and/or improving the immune response, a product for reducing or eliminating the immunosuppressive effect of cells expressing TIGIT (such as Treg cells), and a kit for detecting the presence or absence of TIGIT and the level or activity of TIGIT.

Abstract: Provided are a fusion protein of an anti-TIGIT antibody and IL2 or a variant thereof, and an application thereof. Specifically, a fusion protein is provided, which comprises: (a) a first polypeptide comprising an anti-TIGIT antibody or an antigen-binding fragment thereof; and (b) a second polypeptide comprising interleukin-2 (IL-2) or a variant thereof having a lymphocyte growth promoting activity, the second polypeptide being fused to the first polypeptide. Also provided are an application of such a fusion protein in positively regulating immune cell activity and/or improving immune responses; and/or, an application thereof in the treatment of cancer, immunodeficiency or inflammatory diseases, or infectious diseases.

Abstract: Provided are an anti-TNFR2 monoclonal antibody and an application thereof, Specifically, provided is an TNFR2-targeted monoclonal antibody or an antigen binding fragment thereof, which specifically binds to a cysteine-rich domain (CRD) of human TNFR2. Furthermore, provided are a murine antibody, human-mouse chimeric antibody, and humanized antibody of the TNFR2 antibody, a pharmaceutical composition containing the antibody, and a use thereof in a related disease diagnostic agent and therapeutic drug. The anti-TNFR2 monoclonal antibody has high specificity and high affinity against human TNFR2, can further achieve an immunomodulatory effect, and is used in applications such as anti-tumor, anti-infection and/or anti-autoimmune diseases.